EQS-News

Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months

EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months 22.01.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months

• Induction data read-out expected Q1 2025 from the pivotal Phase 3 ABTECT program evaluating obefazimod in moderately to severely active ulcerative colitis (UC)
• Formal process evaluating oral and injectable combination therapy candidates with obefazimod in UC has commenced; preclinical data to support decision-making on combination agent expected in 2H 2024
• Top-line data from long-term extension trial with 25mg obefazimod once-daily oral after one and two years of treatment expected to read-out in Q3 2024
• IND for Phase 2 trial of obefazimod in Crohn’s disease (CD) cleared; Abivax to consider protocol modifications based on FDA recommendations
• Obefazimod follow-on candidate selection expected in Q3 2024

PARIS, France, January 22, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today provides an outlook on its 2024 strategic priorities and milestones.

Marc de Garidel, Chief Executive Officer of Abivax, says: “We are on track to deliver our strategic roadmap as laid out in September last year to prepare obefazimod for commercialization if approved, starting with ulcerative colitis in the US. Our US office has recently been opened and we have completed the recruitment of a very experienced team with a particular focus in the US. For 2024, our priority stays on the completion of patient recruitment into the ABTECT Phase 3 induction trials.”